Point-of-Care Diagnostics Market Size, Share and Trends 2026 to 2035

What is Point-of-Care Diagnostics Market Size?

The global point-of-care diagnostics market size accounted for USD 64.08 billion in 2025 and is predicted to reach around USD 85.03 billion by 2035, growing at a CAGR of 2.87% from 2026 to 2035. The point of care diagnostics market is driven by the rising incidence of chronic diseases, mainly diabetes. The point-of-care diagnostics market is driven by rising demand for rapid and decentralized diagnostic testing and early disease detection.

Market Highlights

• By Region, North America held a majority revenue share of the point-of-care diagnostics market in 2025.
• By Region, Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By product, the infectious diseases segment held a dominant position in the market with a share in 2025.
• By product, the glucose testing segment is expected to grow at the fastest CAGR in the market between 2026 and 2035.
• By end user, the hospital bedside segment accounted for a considerable revenue share in the market in 2025.
• By end user, the urgent care & retail clinics segment is expected to grow with the highest CAGR in the market during the studied years.

Next-Gen Diagnostics: How AI is Transforming Point-of-Care Testing

Artificial intelligence is significantly improving point-of-care diagnostics by enhancing speed, accuracy, and accessibility of testing. AI algorithms can determine complex datasets, detect subtle patterns in medical images, and also integrate information from numerous sources such as lab tests, imaging, and patient histories, contributing to more precise and timely diagnoses. AI permits more tests to be done at the point of care, closer to individuals, mainly in remote or resource-limited settings. AI algorithms can detect individual patient information to tailor treatment plans and forecast potential future health risks.

Point of Care Diagnostics Market Overview

The medical devices utilized to get an instant result in the investigation (diagnosis & monitoring) of various diseases, such as cancer, diabetes, heart diseases, and others, are referred to as point-of-care (POC) diagnostics. The global point-of-care diagnostics industry has a lot of room for growth for both established and new companies. The point-of-care diagnostics market is growing due to technological developments in POC devices, rising infectious disease incidence, and increased expenditures by key companies. Point-of-care devices provide a much-needed boost in the direction of a patient-centric approach. As a result, the point-of-care diagnostics market may see a significant increase in growth rate during the forecast period.

Point-of-care diagnostics have changed patient care because of their simplicity and efficiency. POC technologies have evolved in efficiency. Point-of-care diagnostics (POC) technologies have evolved and improved as the area of microfluidics has progressed. Microfabrication and microfluidics methods have advanced so much in the last several years that POC devices can now be made at a cheap cost, are simple to use, portable, and produce quick results. In the subject of microfluidics technology, there are numerous research projects underway.

Due to the usage of microfluids, nano diagnostics, and chips, point-of-care diagnostics is gaining widespread acceptability among patients throughout the world. The samples are taken from the patient's site for completing tests, and findings can be obtained in a very short amount of time.

Point-of-Care Diagnostics Market Growth Factors

The medical devices utilized to get an instant result in the investigation (diagnosis & monitoring) of various diseases, such as cancer, diabetes, heart diseases, and others are referred to as point-of-care (POC) diagnostics in this report. The global point-of-care diagnostics industry has a lot of room for growth for both established and new companies. The point-of-care diagnostics market is growing due to technological developments in POC devices, rising infectious disease incidence, and increased expenditures by key companies.

The rising occurrences of target disorders, as well as the increased prevalence of infectious diseases such as tuberculosis and AIDS, are boosting the expansion of the point of care diagnostics industry. The growing desire for rapid tests among the general public is also helping the point-of-care diagnostics industry grow. The need to make the healthcare sector more patient-centered is proven to be a positive factor in the point-of-care diagnostics market's growth rate. Many patients may find the centralized testing method inconvenient because of it necessitates multiple trips to clinics to complete the entire evaluation process. Point of care devices provides a much-needed boost in the direction of a patient-centric approach. As a result, the point-of-care diagnostics market may see a significant increase in growth rate during the forecast period.

Point-of-care diagnostics has changed patient care because of their simplicity and efficiency. POC technologies have evolved efficiency. Point-of-care diagnostics (POC) technologies have evolved and improved as the area of microfluidics has progressed. Microfabrication and microfluidics methods have advanced so much in the last several years that POC devices can now be made at a cheap cost, are simple to use, portable, and produce quick results. In the subject of microfluidics technology, there are numerous research projects underway.

Due to the usage of micro fluids, nano diagnostics, chips, point-of-care diagnostics is gaining widespread acceptability among patients throughout the world. The samples are taken from the patient's site for completing tests, and findings can be obtained in a very short amount of time.

The increased frequency of chronic and infectious in developing economies is one of the primary factors driving the growth of point-of-care diagnostics market. The chronic diseases such as rheumatism, diabetes, and cancer are on the rise around the world for a variety of causes, including an ageing population, unhealthy lifestyle, and environmental factors.

The adoption of glucose monitoring testing kits is driven by factors such as the need for early detection of hyperglycemic and hypoglycemic diabetes, the high prevalence of diabetes, the convenience of continuous glucose monitoring over traditional monitoring, availability of glucose monitors, and increased awareness of the products around the world, and growing technological innovations.

Point-of-Care Diagnostics Market Outlook

• Industry Growth Overview: Between 2025 and 2034, the point-of-care diagnostics market is expected to grow rapidly due to rising demand for quick and near-patient testing solutions. This growth is driven by the increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and infectious diseases. Additionally, higher healthcare spending in emerging economies and growing awareness of the importance of early disease detection are supporting market expansion.
• Innovation & Technology Trends: Technological advancements are transforming the POC diagnostics landscape, with innovations in microfluidics, lab-on-a-chip systems, and molecular diagnostic platforms. Accuracy, speed, and remote monitoring of POC tests are being improved through AI-based analysis and cloud connectivity. Companies are focusing on multiplex testing, where multiple biomarkers can be detected on a single sample. POC solutions are becoming more user-friendly, accessible, and suitable for a wide range of clinical environments thanks to these innovations.
• Global Expansion: Market leaders are strategically expanding their geographic reach to meet increasing demand and take advantage of favorable regulatory environments. Companies like Siemens Healthineers, Thermo Fisher Scientific, and Roche are setting up hubs and service centers in the region to ensure quick delivery and technical support. The international expansion also helps these companies meet regulatory compliance and local quality standards, making market entry easier.
• Major Investors: Investment activity in the POC diagnostics industry is accelerating as it attracts attention from private equity, venture capital, and strategic investors, along with its growth potential. The technical barriers to entry are high, healthcare diagnostic resilience remains steady, and the sector aligns well with government health initiatives, making it appealing. The influence of major financial players is also boosting R&D projects and the commercialization of next-generation POC solutions.
• Startup Ecosystem: The POC diagnostics startup ecosystem is rapidly growing, driven by innovation, unmet clinical needs, and venture capital funding. New molecular testing platforms, AI-enabled diagnostics, and integrated digital healthcare solutions are emerging within startups to improve accessibility and efficiency. Collaborations with hospitals, research institutions, and pharmaceutical companies are helping these startups grow quickly. Additionally, product development is becoming more inclusive and globally impactful, emphasizing affordability, scalability, and sustainability.

Point-of-Care Diagnostics Market Trends

Advancements in Microfluidics and Portable Diagnostic Devices: Microfluidics and diagnostics on the go are moving forward in revolutionizing the accuracy, cost, and simplicity of tests. This development enables the integration of the device to deliver consistent data in minutes.

• Rising Diabetes Awareness: Rising diabetes awareness and growing prevalence are fueling the rise in the use of advanced glucose monitoring solutions such as portable blood glucose testing devices and continuous glucose monitoring.
• Rising Burden of Chronic and Infectious Diseases: Increased burden of chronic and infectious diseases needs a quick diagnostic solution. In the healthcare space, the evolution of implementation is progressing to early detection, monitoring, and quick decision-making at the point-of-care using mobile devices.
• Growing Adoption of Patient-Centric Healthcare: Portable testing devices can reduce the number of hospital visits and improve the availability of health services, enhance treatment efficiency, and facilitate tailored treatment and disease management.

Strategic Growth Opportunities

• Expansion in Home-Based Diagnostics: Greater access to the market for self-testing kits and remote patient monitoring offers great commercial potential. The growing need for consumers to get access to diagnostic services in the comfort and convenience of their own homes, as quickly as possible, is nudging manufacturers to develop home-use diagnostic portfolios.
• Integration of AI and Digital Health Technologies: With smartphones, cloud platforms, and data analysis, POD diagnostics is transforming due to AI. New growth opportunities will occur from the ability of smart diagnostic devices to make real-time data sharing and clinical decision support possible.
• Geographic Expansion in Emerging Markets: The market in the Asia Pacific, LATAM, and AMEA regions is expected to have great potential as healthcare infrastructure is continuously being developed in these regions. The potential to grow into underserved areas is supported by increased investments by governments, healthcare access, and disease burden.
• White Space in Multiplex and Molecular Diagnostics: The need for mobile molecular diagnostics is very great and could potentially be able to detect multiple disease states from a single sample. A need for a more cost-effective multiplex platform for primary and rural health care exists.
• Personalized and Preventive Healthcare Opportunities: Precision Medicine and preventive medicine are gaining spotlight, and hence, the demand for rapid diagnostic biomarkers is rising. If companies are planning to create a personalised level of care testing solution, long-term competitive advantages can be achieved while incorporating chronic disease management.

Market Scope

Market Dynamics

Drivers

Rising Tide of Chronic Disease in the United States

How is the increasing prevalence of chronic and infectious diseases the driver for the point-of-care diagnostics market?

The increasing prevalence of both chronic and infectious diseases is a major driver for the point-of-care diagnostics market. This is because point-of-care testing provides faster, more accessible, and usually more cost-effective diagnostic solutions, which are mainly beneficial for managing these conditions. Point-of-care molecular diagnostics provide faster turnaround times for infectious disease testing, vital for prompt diagnosis as well as treatment initiation, mainly for highly contagious diseases.

Restraint

How does complexity in regulations and reimbursement policies restrain the point-of-care diagnostics market?

Complexity in regulations and reimbursement policies significantly restrains the point-of-care diagnostics market by increasing costs, delaying market entry, and hindering widespread adoption. These factors disproportionately affect smaller firms and those in resource-restricted settings. Securing reimbursement for point-of-care tests, especially in community or home settings, can be challenging due to varying policies along with the preference for conventional testing methods. Shortage of clear reimbursement pathways can discourage acceptance, even when tests are available.

Opportunity

How are technological advancements an opportunity for the point-of-care diagnostics market?

Technological advancements are driving significant growth and opportunity within the point-of-care diagnostics market. Innovations such as miniaturization, biosensors, microfluidics, AI integration, and multiplexing capabilities are making point-of-care testing quicker, more accurate, and more accessible, contributing to increased adoption over various healthcare settings. Technological advancements are contributing to smaller, more portable point-of-care devices, permitting testing in diverse settings such as mobile healthcare units, remote clinics, and even at home.

Segment Insights

Product Insights

The cardiometabolic diseases segment is projected to grow at a notable pace owing to its conquering prevalence of diabetes, cardiovascular diseases, and obesity globally. Growth in the market is driven by the rise in demand for rapid glucose, cholesterol, and cardiac biomarker testing. The accuracy and portability of diagnostic devices are improving due to technological advances. The growing importance of early detection and continuous monitoring of the patient is driving the uptake. The segment will be projected to grow at a positive rate with the anticipated growth due to a favorable health initiatives and awareness.

The pregnancy & infertility testing segment is expected to witness steady growth during the forecast period due to the advancing demand for convenient and quick pregnancy and infertility testing solutions. There is a growing awareness of reproductive health and family planning that is facilitating the adoption of products. Testing kits are available at home, which offer privacy, ease, and provide instant results. Technological advances are leading to greater sensitivity and reliability of tests. The market is expected to grow following the rising rate of infertility and the rising access to self-testing products.

End User Insights

The physician's office lab segment is projected to grow at a notable pace as it relies heavily on the use of rapid innovations and diagnostic test kits that can be used instantly for clinical decision-making. Demand is being boosted by the growing number of patients and the desire to shorten turnaround time in the lab. There has been a significant improvement in the efficiency of workflow in physician offices with the adoption of new compact diagnostic equipment. The increasing acceptance of decentralized healthcare systems is expected to help segment growth.

The homecare/self-testing segment is expected to witness steady growth during the forecast period due to the steady use of convenient and easy-to-use diagnostic devices. Rising awareness of preventive healthcare and chronic disease management is encouraging self-testing. Home diagnostic kits are also more accurate and available due to technological advances. Increasing availability of digital health platforms is enhancing remote patient monitoring. The preference of consumers for personalized healthcare solutions is likely to drive the market to witness exponential growth.

Regional Insights

What are the Advancements of the Point-of-Care Diagnostics Market in North America?

North America dominated the global market in 2025 due to the advanced adoption of diagnostic technologies and well-established healthcare infrastructure. The prevalence of chronic diseases, such as diabetes mellitus and cardiovascular disorders, is increasing and creating an unmet demand for “pathfinder” diagnostic approaches that are fast and accurate. Market expansion is backed by increasing investments in decentralized healthcare and digital health technologies. Supportive regulatory structures and favorable reimbursement policies support implementation of POTs. Increasing use of home-based diagnostics and remote patient monitoring is further driving growth.

U.S. Point-of-Care Diagnostics Market Size and Growth 2026 to 2035

The U.S. point-of-care diagnostics market size is valued at USD 18.87 billion in 2025 and is expected to reach around USD 25.23 billion by 2035, growing at a CAGR of 2.95% from 2026 to 2035

U.S. Point-of-Care Diagnostics Market Analysis

The North American point-of-care diagnostics market is dominated by the U.S., driven by its advanced healthcare infrastructure, favorable reimbursement policies, and adoption of innovative devices. Growth is supported by large-scale manufacturers investing in R&D and direct-to-consumer platforms. Additionally, government health initiatives and early detection programs accelerate the adoption of next-generation POC devices.

With the rising incidence and prevalence of lifestyle diseases in North America, the region is gaining traction. The greater awareness of self-testing and home care kits, as well as considerable adoption of novel technologies, are expected to boost the growth of the point of care diagnostics market in the North America.

On the other hand, the Asia-Pacific is estimated to be the most opportunistic segment during the forecast period. Due to the increasing number of market players exploring the region's untapped economies, the Asia-Pacific market is expected to grow significantly over the forecast period. Furthermore, the increased use of point of care diagnostics kits in countries such as China, Japan, and India is a key driver of growth in the Asia-Pacific region.

China Market Trends

China's point-of-care diagnostics market is anticipated to grow significantly, due to the increasing trend in healthcare spending and access to medical services. The growing healthcare utilization of rapid diagnostic testing devices in healthcare centers is attributed to the rising prevalence of chronic and infectious diseases. Increasing healthcare utilization of rapid diagnostic testing devices in healthcare centers is attributed to rapid diagnostic testing for the growing prevalence of chronic and infectious diseases. The market is growing at a fast pace as a result of government efforts targeted at healthcare modernization and promoting domestic medical device manufacturing.

Europe is expected to grow significantly in the point-of-care diagnostics market during the forecast period. Europe is experiencing a rise in the incidence rates of various diseases, along with the rise in adoption of new technologies. This increases the demand for the use of point-of-care diagnostics within the population. Thus, this promotes the market growth.

UK

The industries in the UK are utilizing various technological advancements in the development of new point-of-care diagnostics kits. At the same time, rising diseases are increasing their use. This increases their production, which in turn increase the collaboration among the industries.

Germany

There is a rise in the demand for the use of rapid point-of-care diagnostics approaches. Thus, new research is being conducted for their development to deal with the rising diseases. This is further supported by the government fundings.

India Point-of-Care Diagnostics Market Trends

India is emerging as one of the fastest-growing markets in the Asia-Pacific POC diagnostics sector, driven by increasing healthcare accessibility and growing awareness of chronic diseases. Government initiatives promoting preventive healthcare and rural diagnostic outreach programs further support adoption. Additionally, localized manufacturing and strategic partnerships with local distributors help accelerate market expansion.

How is the Opportunistic Rise of Latin America in the Point-of-Care Diagnostics Market?

Latin America is expected to experience notable growth in the market, driven by rising healthcare investment and increased awareness of POC diagnostics. In countries like Brazil and Mexico, regulatory reforms and stronger public-private partnerships are improving market access. Growth is further supported by expanding rural healthcare infrastructure and the increasing presence of retail health outlets. Brazil holds the largest portion of the market in Latin America, driven by Manufacturers' focus on developing affordable, region-specific products to meet local needs. Expanding urban and semi-urban healthcare infrastructure is expected to further broaden market penetration.

Brazil Market Trends

Brazil's point-of-care diagnostics market is anticipated to grow significantly. Point-of-care testing devices are being used increasingly due to an increase in chronic diseases and infectious diseases. The increasing market conditions are developing under the government's movement towards the improvement of access to healthcare. The government's work for improvement of healthcare accessibility in the market. Growth in private health facility infrastructure is helping private healthcare testing volumes. The rising consciousness about preventive care and early diagnosis is fueling the demand for portable diagnostics technologies. Increasing investments in laboratory modernization and digital health are supporting innovation.

What Potentiates the Growth of the Point-of-Care Diagnostics market in the Middle East & Africa (MEA)?

The Middle East & Africa POC diagnostics market is expected to grow moderately, driven by improving healthcare infrastructure and rising government expenditure. Adoption is boosted by investments in telehealth and decentralized healthcare models, particularly in GCC countries. Affordability remains a concern, but the introduction of region-specific, lower-cost devices is likely to increase usage.

Saudi Arabia Market Trends

Saudi Arabia market is anticipated to grow significantly, owing to the rise in healthcare investment in infrastructure development. The government's promise for digitalization of healthcare and advanced medical technologies is helping to boost market growth. Point-of-care diagnostics is being adopted rapidly due to the growth in the establishment of hospitals, diagnostic centers, and primary healthcare facilities. This nation is seeing increased interest in portable diagnostic tools which enable quicker clinical decisions. New diagnostic technologies are being rolled out as part of the expansion of investments in public and private healthcare.

UAE Point-of-Care Diagnostics Market Evolution

The UAE leads the market in the Middle East & Africa, driven by strong government investment in healthcare infrastructure and advanced diagnostic services. Strategic partnerships with global manufacturers ensure the availability of technologically advanced devices. Affordable and easy-to-use tests are further gaining traction in urban and semi-urban areas.

Government Initiatives

India

The Government of India expedited the Strengthening of Medical Devices Industry (SMDI) scheme to incentivise production, R&D, and innovation of medical devices in India and to enhance its medical device ecosystem and ensure access to its medical devices with cutting-edge technology. (Source: https://www.pib.gov.in)

United States

The U.S. FDA continued to expand regulatory pathways for innovative point-of-care diagnostic devices via its Breakthrough Devices Program and fast-track technologies to bring them to patients.

China

To implement the Healthy China 2030 initiative, China introduced measures to enhance the capacity of the primary care sector and boost utilization of rapid diagnostic technologies for diagnosing diseases while providing healthcare services to circulate broad access to the health system.

Saudi Arabia

In line with Saudi Arabia's Vision 2030, healthcare transformation efforts were also significantly continued, with a focus on introducing advanced diagnostic technology, modernizing laboratories, and rolling out decentralized healthcare systems to facilitate prompt diagnosis of diseases and enhance the country's healthcare capabilities.

Investment Landscape

In June 2026, Roche again confirmed its €600 million investment in a highly innovative new diagnostic manufacturing center in Penzberg, Germany, which should boost manufacturing capacity for advanced diagnostic technologies. The investment is helping the company build its long-term manufacturing potential, while assisting in meeting the rising demand for diagnostic solutions globally. . (Source: https://www.reuters.com)

• In May 2025, Roche Diagnostics made the US$550m investment commitment to grow its diagnostics manufacturing base in Indianapolis. The plan will boost the output of continuous glucose monitoring technologies, as well as generate hundreds of additional jobs. . (Source: https://diagnostics.roche.com)

Collaboration Landscape

• In May 2025, Roche entered a strategic agreement with Broad Clinical Labs (BCL) to explore Roche's Sequencing by Expansion (SBX) technology for the rapid sequencing of the entirety of an individual's genome to be used in the initial stages for critically ill newborns. The partnership intends to facilitate the uptake of clinical diagnostics technologies of the future.

Competitive Landscape

The point-of-care diagnostics market is semi-consolidated, with large companies dominating rapid testing and portable analyzers and smaller players focusing on specific illnesses. There is an average barrier to entry for niche diagnostics, but a high barrier to entry for multi-analyte platforms requiring regulatory approval. Key players include Abbott, Roche, and Danaher, with emerging players such as LumiraDx that emphasize connectivity and multiplexing capabilities, while niche players provide solutions for cardiac markers, HbA1c, and pregnancy testing.
Some of the strategic initiatives involve acquisitions of molecular test start-ups, partnerships with telehealth companies for remote testing, and development of multiplex COVID-19, flu, and RSV tests. The market is benefiting from the development of AI in result analysis and the use of microfluidic cartridges for accurate point-of-care testing. Barriers faced by upcoming players include regulatory norms in the form of CLIA waiver requirements and substantial research and development costs for reagent stability.

Point-of-Care Diagnostics Market – Value Chain Analysis

• Reagents and Consumables Sourcing
  The foundation of POC diagnostics lies in the supply of high-quality reagents, antibodies, enzymes, and assay kits, which are critical for accurate and rapid testing.
  Key Players: Thermo Fisher Scientific, Sigma-Aldrich (Merck), bioMérieux, Sekisui Diagnostics
• Component & Device Fabrication
  Raw materials and reagents are processed into components such as test strips, microfluidic chips, cartridges, and lateral flow devices used in POC instruments.
  Key Players: Abbott Laboratories, Roche Diagnostics, BD (Becton, Dickinson and Company), Nova Biomedical
• Instrument / Analyzer Manufacturing
  Components are integrated into portable or benchtop analyzers, handheld devices, and molecular testing platforms. Devices undergo strict calibration, quality control, and safety testing.
  Key Players: Siemens Healthineers, Danaher (Cepheid, Beckman Coulter), Roche Diagnostics, Abbott Laboratories
• Software & Connectivity Integration
  Advanced POC systems incorporate data analytics, connectivity to electronic health records (EHR), and cloud-based monitoring for real-time results and decision support.
  Key Players: Siemens Healthineers, Roche Diagnostics, Thermo Fisher Scientific, BD
• Distribution & Deployment
  Finished POC devices and test kits are supplied to hospitals, clinics, laboratories, pharmacies, and even home-care settings, supported by training and technical services.
  Key Players: Abbott Laboratories, Roche Diagnostics, bioMérieux, BD, Thermo Fisher Scientific
• Post-Market Support & Maintenance
  Ongoing service, software updates, calibration, and regulatory compliance support ensure device accuracy and longevity in clinical environments.
  Key Players: Siemens Healthineers, Danaher, Abbott Laboratories, Roche Diagnostics

Top Companies in the Point of Care Diagnostics Market & Their Offerings

• Abbott Laboratories: Offers a massive POC portfolio featuring the ID NOW rapid molecular platform and i-STAT handheld blood analyzers for immediate bedside results.
• Bio-Rad Laboratories Inc.: Focuses on specialized POC solutions like the D-10 system for rapid diabetes monitoring and portable toxicology screening tools.
• Cardinal Health Inc.: Operates primarily as a distributor of POC diagnostic kits and supplies, providing healthcare facilities with a centralized source for various rapid testing brands.
• Cepheid: Developed the GeneXpert system, a modular platform that provides gold-standard molecular results for infectious diseases in under an hour at the point of care.
• F. Hoffmann-La Roche Ltd: Provides high-end POC systems like the cobas line for cardiac markers and infectious diseases, alongside their industry-leading Accu-Chek diabetes products.
• Mesa Biotech: Now part of Thermo Fisher Scientific, they created the Accula platform, a palm-sized PCR system used for rapid molecular detection of respiratory viruses.
• Quest Diagnostics Incorporated: Primarily a lab service provider that supports the POC market by offering management services and connectivity solutions for decentralized testing sites.
• Quidel Corporation: Now QuidelOrtho, they dominate the rapid immunoassay market with the Sofia fluorescent analyzer and QuickVue lateral flow tests.

Recent Developments

• In December 2025, Cobas liat point-of-care PCR test for Bacteriaceae infections was approved by the FDA 510 (k) with CLIA waiver and CE IVDR certification, providing results within 15 minutes and allowing differentiation among three species that cause whooping cough. (Source: https://www.roche.com )
• In November 2025, Sapphiros entered into a strategic supply deal with Roche, giving exclusive rights to purchase at least one billion lateral flow test kits per year manufactured from Sapphiros' factory located in the U.K., as well as to its multiplex molecular platform. (Source: https://sapphiros.com)
• In August 2025, Anbio Biotechnology introduced the AP-100 Ultra-Fast PCR system, a compact device weighing 668g that provides laboratory-quality PCR results from samples in just 15 minutes without any nucleic acid extraction, making it suitable for use in detecting outbreaks either on-site or while being transported. (Source: https://www.prnewswire.com)
• In October 2023, EKF Diagnostics opened its new state-of-the-art life sciences manufacturing facility in the U.S. This facility is designed to address the increasing demand of an expanding customer base.(Source: https://www.ekfdiagnostics.com)
• In February 2023, bioMérieux received U.S. FDA approval for its BIOFIRE SPOTFIRE respiratory panel system to expand its POC testing product range.
  (Source: https://www.biomerieux.com)
• In January 2023, Cipla announced the launch of Cippoint, a point-of-care testing device with testing of cardiac markers, diabetes, infectious diseases, thyroid function, inflammation, metabolic, and coagulation markers.(Source: https://drugscontrol.org)
• In May 2025, for the detection of Respiratory Syncytial Virus (RSV), SEKISUI Diagnostics, which is a global medical diagnostics manufacturer, has launched a new rapid diagnostic testing tool in professional healthcare settings, as per the recent announcements.
• In May 2025, a Medicare reimbursement coverage for its FebriDx test, which is a rapid point-of-care (POC) diagnostic used to distinguish between bacterial and non-bacterial acute respiratory infections, from US Medicare Administrative Contractor (MAC) to Lumos Diagnostics was recently confirmed.
• In May 2025, a collaboration between Neo Medical Inc, which is an innovator in handheld ultrasound technology, and the POCUS Certification Academy, a globally recognized provider of point-of-care ultrasound (POCUS) education and Inteleos which is non-profit organization, was announced. To educate, increase proficiency, and to enhance access to advanced diagnostic technology worldwide is the aim of this collaboration.

Segments Covered in the Report

By Product

• Blood Glucose Monitoring
• Infectious Diseases
• Cardiometabolic Diseases
• Pregnancy & Infertility Testing
• Hematology Testing
• Others

By End User

• Hospital Bedside
• Physician's Office Lab
• Urgent Care & Retail Clinics
• Homecare/Self-testing

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa